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Abstract
It is now widely recognized that BPV-1 and less commonly BPV-2 are the causative agents of equine sarcoids. Here we present the generation of
equine cell lines harboring BPV-1 genomes and expressing viral genes. These lines have been either explanted from sarcoid biopsies or generated in
vitro by transfection of primary fibroblasts with BPV-1 DNA. Previously detected BPV-1 genome variations in equine sarcoids are also found in
sarcoid cell lines, and only variant BPV-1 genomes can transform equine cells. These equine cell lines are morphologically transformed, proliferate
faster than parental cells, have an extended life span and can grow independently of substrate. These characteristics are more marked the higher the
level of viral E5, E6 and E7 gene expression. These findings confirm that the virus has an active role in the induction of sarcoids and the lines will be
invaluable for further studies on the role of BPV-1 in sarcoid pathology.
© 2008 Published by Elsevier Inc.Keywords: Bovine papillomavirus type 1; Equine; Sarcoid; Cell line; TransformationIntroduction
Equine sarcoids are locally invasive, fibroblastic skin tumors
and represent the most common skin tumor in equids worldwide
(Jackson, 1936; Ragland et al., 1970; Pascoe and Summers,
1981). Many studies have reported an association with bovine
papillomavirus (BPV) infection based on the presence of BPV-1/
2 DNA sequences in the majority of sarcoid tumors (Otten et al.,
1993; Bloch et al., 1994; Reid et al., 1994; Martens et al., 2001;
Chambers et al., 2003b). Papillomaviruses belong to a large
family of animal and human papillomaviruses that normally
infect epithelial cells causing hyperproliferative lesions including
warts, papillomas or condylomas. Some types of PVs, including
BPV types 1 and 2, can also infect fibroblasts and induce benign
fibropapillomas. PVs are normally strictly species-specific
and the equine sarcoid represents the only documented case of
natural cross-species PV infection (Lancaster et al., 1979;⁎ Corresponding author. Division of Pathological Sciences, Institute of
Comparative Medicine, University of Glasgow, Faculty of Veterinary Medicine,
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doi:10.1016/j.virol.2007.11.037Gorman, 1985). We and others have shown that many of the
BPV viral genes are expressed in sarcoids (Nasir and Reid, 1999;
Carr et al., 2001; Chambers et al., 2003a), with the highest levels
detected in nodular sarcoids (Bogaert et al., 2007) supporting
active papillomavirus infection. The viral genome is maintained
episomally (Amtmann et al., 1980; Yuan et al., 2007a), and while
genome copy number can vary, infection in the horse is
maintained at a high genome copy number (Yuan et al., 2007a).
In addition we have shown that sarcoids are associated with
BPV-1 variant sequences (Chambers et al., 2003b;Nasir andReid,
2006; Nasir et al., 2007). In this paper we report the establishment
and characterization of equine fibroblast cell lines originating
from sarcoid tumor biopsies and from equine fibroblasts
transfected with full-length BPV-1 DNA isolated from a sarcoid.
Results
Establishment of EqPalFs harboring BPV-1 genomes and sarcoid
fibroblast cell lines
The full-length 8 kbp BPV-1 genome was isolated from three
sarcoid DNA samples (S5, S6, S11) using RCA. The genomes
Table 1
BPV-1 E5 and LCR variants in sarcoids and cell lines
E5 variant LCR variant
Tumor
S5 Sw I LCR II
S6 Sw I LCR II
S11 Sw IV LCR V
Cell line
S6-1, -2, -3 Sw I LCR II
EqS01a B III LCR II
EqS02a Sw I LCR IV
EqS04b Sw I LCR VII⁎
⁎E5 and LCR variants are described in Chambers et al. (2003b), Yuan et al.
(2007a,b) and Nasir et al. (2007). LCR VII represents a novel variant and
comprises the nucleotide changes detected in LCR IVand additional substitutions:
G7266A, C7836G, and A7882T.
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equine fetal palate cells, EqPalF cells. BPV-1 genomes from S5
and S6 were selected for transfection since both of these viral
genomes comprise the most frequent BPV-1 variants (E5, LCR)
in our bank of sarcoids (Chambers et al., 2003b; Yuan et al.,
2007a; Nasir et al., 2007) (Table 1). Similarly, BPV-1 from a
bovine papilloma was used to transfect EqPalFs. None of the
cells transfected with control plasmids (pcDNA3.1, pEGFPC3)
survived G418 selection. The transfections with the ‘bovine’
BPV-1 were performed twice in triplicate, however the cells
were unable to survive. Cells transfected with BPV-1-S11 were
also unable to survive. In contrast, cells transfected with BPV-1-
S5 or -S6 grew out after 3 weeks of G418 selection and cells
transfected with BPV-1-S6 grew faster than cells transfected
with -S5. Three clones of S6-transfected cells (S6-1, S6-2 and
S6-3) were isolated and grown.
Three naturally occurring sarcoid tumors were explanted into
cultured cells and these were termed EqS01a, EqS02a, and
EqS04b. PCR analysis and DNA sequencing confirmed that all
three tumors harbored BPV-1 variant genomes, as listed in
Table 1.
Morphology
Cell morphology was assessed by light microscopy (Fig. 1).
The S6 and EqS cells grew as monolayers and exhibited a fairlyFig. 1. Cell morphology of BPV-1 transformed EqPalFs (S6-2), sarcoid-derived EqS
×100 magnification.uniform elongated spindle shape morphology compared to
EqPalF cells. In both cell types the cells were tightly packed and
showed loss of contact inhibition. Since BPV-1 E5 has been
shown to be able to disrupt the actin cytoskeleton contributing
to the transformed phenotype (Tsirimonaki et al., 2006), we
examined the actin cytoskeleton of BPV-1 equine fibroblasts.
EqPalF, S6-1, S6-2 and EqS04b cell lines were stained with
TRITC-conjugated phalloidin which stains the actin filaments.
As shown in Fig. 2, no obvious differences in the actin
cytoskeleton were observed in the BPV-1 transformed cells
compared to EqPalF control cells.
Analysis of status and load of viral genomes
To determine the status of the viral genomes, DNA, digested
with HindIII, which cuts the BPV-1 genome once, was
subjected to Southern blot analysis using a α-32P labeled
BPV-1 probe. As shown in Fig. 3A, in EqS cells, a single band
of approximately 8 kbp was detected indicating that these cells
contain episomal BPV-1 whole genomes. In EqS01a cells, a
smaller band was also evident suggesting that these cells may
also contain a BPV-1 variant genome of a smaller size.
Similarly, Southern blot analysis of the S6 cells showed that
S6 cells harbor episomal BPV-1 genomes. To further confirm
these data, RCA which amplifies circular DNA was performed
on the same DNA samples. The results confirm the presence of
8 kbp episomal genomes (Fig. 3B). They also show the presence
of the smaller band in EqS01a cells. To determine the BPV-1
viral load in each cell line, DNAwas isolated from early passage
(p5) cells and subjected to Absolute Quantitative (AQ) PCR. As
shown in Fig. 3C, EqS04b cells harbor the highest number of
BPV genomes per cells (8 g.e.) and EqS02a cells the lowest
(1 g.e.). The remaining cell lines all contain 2 BPV genomes per
cell.
Cells harboring a high viral load show a high level of viral
oncogene expression
No BPV-1 mRNAwas detected in EqPalF cells. In contrast,
both early and late viral BPV-1 gene transcripts could readily be
detected by RT-PCR in EqS and S6 cells. The PCR amplification
profile for S6-2 cells is shown in Fig. 4A. To determine the01a fibroblasts (EqS01a) and control EqPalF cells assessed by light microscopy.
Fig. 2. Actin immunofluorescence of BPV-1 transformedEqPalFs (S6-1, S6-2), sarcoid-derived fibroblasts (EqS04b) and control EqPalF cell assessed by light microscopy.
Representative images are shown.
Fig. 3. (A) Southern blot analysis of HindIII digested DNA from sarcoid derived
fibroblasts (lanes 1–3), BPV-1 transformedEqPalFs (lanes 4–6), EqPalF negative
control cells (lane 7) and BPV-1 plasmid (lane 8). The blot was hybridized with a
BPV-1 probe. (B) RCA of BPV DNA in sarcoid derived fibroblasts (lanes 1–3)
andBPV-1 transformedEqPalFs (lanes 4–6). Products of RCAwere digestedwith
HindIII prior to electrophoresis. (C) BPV-1 genome copy number in sarcoid
derived fibroblasts (EqS01a, EqS02a, EqS04b) and BPV-1 transformed EqPalFs
cells (S6-1, S6-2, S6-3) determined by AQ-PCR.
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expression of BPV-1 oncogenes E5, E6 and E7 was assessed by
relative quantitative (RQ) RT-PCR. EqS02a cell line was
arbitrarily assigned as the calibrator since this cell line showed
the lowest levels of oncogene expression (Fig. 4B). The highest
levels of E5, E6 and E7 oncogene expression were detected in
EqS04b cells. These cells contain the highest viral load (8 BPV
genomes per cell). The lowest levels of E5 expression were
detected in EqS01a cells which contain 2 genomes per cell and
the lowest levels of E6 and E7 expression were detected in
EqS02a cells harboring one BPV genome per cell.
Cells with high levels of BPV-1 oncogene expression show
enhanced cell proliferation
The proliferation potential of cells was assessed by MTT
assays. As shown in Fig. 5A, all BPV-1 expressing cell lines
showed a growth advantage compared to the control EqPalF
cells. To further examine the effect of BPV-1 oncogene
expression on cell proliferation, the population doubling times
were determined and are presented in Fig. 5A. In agreement with
the MTT assays, EqPalFs exhibited the longest P.D. time
(57.8 h). In contrast, the P.D. time was much shorter for all BPV-
1 expressing cells. Cells with the highest levels of oncogene
expression, EqS04b, S6-1 and S6-2 exhibited shorter P.D. times
(26.7, 26.2 and 24.0 h, respectively). Conversely, cells with low
viral load and relatively low levels of oncogene expression
(EqS02a, EqS01a and S6-3) exhibited longer P.D. times of 37.2,
30.7 and 32.6 h, respectively. EqPalF, S6-2 and EqS01a cells
were analyzed for the expression of the proliferation marker,
Ki67. As shown in Fig. 5B, both S6-2 and EqS01a exhibited
greater Ki67 positive staining, of 21 (±1.8)% and 23 (±2.5)%
respectively, compared to EqPalF cells in which 12(±2.1)% of
cells were stained positively.BPV-1 expressing equine fibroblasts show anchorage
independent growth
To assay for anchorage independent growth, primary
EqPalFs, EqS and S6 cells were cultured in medium containing
methylcellulose for 14 days. ConBPV-1 cells were used as a
Fig. 4. (A) RT-PCR analysis of BPV-1 gene expression in S6-2 cells. (B) RQ-RT-
PCR analysis of BPV-1 E5, E6 and E7 oncogene expression in sarcoid derived
fibroblasts (EqS01a, EqS04b, EqS02a) and BPV-1 transformed EqPalFs cells
(S6-1, S6-2, S6-3). Expression is shown relative to the calibrator EqS02a, the
value for which has been set to 1.
Table 2
Anchorage independence assay
Cell line Focus formation per 10,000 cells
EqPalF 0
ConBPV1 138.0±14.1
S6-1 10.4±1.1
S6-2 11.8±3.1
S6-3 8.4±1.7
EqS01a 0
EqS02a 0.9±0.7
EqS04b 67.0±25.4
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control EqPalF cells failed to form foci. In contrast, all cell lines,
with the exception of EqS01a cells, were able to grow in
methylcellulose media. The efficiency of focus formation was
highest in EqS04b cells, similar to the ConBPV-1 control cells,
and lowest in EqS02a cells. The S6 cells all showed similar
efficiency of focus formation but the efficiency was much lower
than the positive control cells.Fig. 5. (A) Cell proliferation and population doubling (P.D.) times of BPV-1 transform
EqS02a). (B) Ki67 immunoreactivity in EqPalF, S6-2 and EqS01a cells.The S6 and EqS cells were also assessed for growth in serum
free medium. None of the cell lines examined, including the
ConBPV-1 control cells, were able to grow in the absence of
serum (data not shown). In the presence of 1% serum, only the
EqS cells were able to grow, although their growth was slower
than in the presence of 10% serum (Fig. 6).
BPV-1 can extend the life span of transformed cells but is not
able to immortalize cells
Several of these cell lines (S6-2, EqS01a, EqS02a and
EqS04b) have now been maintained long term. Control EqPalFs
showed a limited life span of approximately 13 passages (∼19
P.D.) whereas S6-2 and EqS01a were able to grow to passage 21
(∼33 P.D.) and 30 (∼39 P.D.), respectively, followed by growth
arrest. This suggests that BPV-1 extends the life span of equine
fibroblasts but is not able to immortalize them. However, the
sarcoid lines EqS02a and EqS04b have gone through 16
passages (∼34 P.D.) and 24 passages (∼60 P.D.) respectively
and at present show no signs of growth arrest.ed EqPalF (S6-1, S6-2, S6-3) and sarcoid-derived fibroblasts (EqS01a, EqS04b,
Fig. 6. Cell proliferationmeasurements of BPV-1 transformed EqPalF (S6-1, S6-2,
S6-3) and sarcoid-derived fibroblasts (EqS01a, EqS02a, EqS04b) in 1% serum,
assessed by the MTT assay.
356 Z.Q. Yuan et al. / Virology 373 (2008) 352–361BPV-1 expressing fibroblasts show perinuclear/cytoplasmic
p53 expression
Several studies have shown that p53 expression is cytoplas-
mic/perinuclear in sarcoid in vivo (Johnston et al., 1996;
Martens et al., 2000; Nixon et al., 2005; Bogaert et al., 2007).We
have also previously demonstrated that the transactivation
function of p53 is abrogated in sarcoid cells (Nixon et al.,
2005). To determine whether the cell lines derived in this study
also express cytoplasmic p53, p53 protein expression was
evaluated in EqS01a, S6-2 and control EqPalFs. As demon-
strated in Fig. 7, both S6-2 and EqS01a cells show almost total
perinuclear/cytoplasmic localization of the p53 protein confirm-
ing previous in vivo observations.
Discussion
The involvement of BPV-1 in the induction of equine
sarcoids is now almost universally accepted. Little however is
known about the molecular pathology underlying the tumor and
the mechanisms used by BPV-1 to induce the tumor. The
present study was aimed at the generation of cell lines from
sarcoids and of cell lines transformed by BPV-1 that could help
the elucidation of the role of the virus in transformation and
serve as in vitro model systems for future studies.Fig. 7. p53 immunoreactivity using CM-1 anti-p53 antibody in BPV-1 transformed E
×400 magnification.Generation of equine cell lines
We have developed three sarcoid-derived cell lines (EqS01a,
EqS02a and EqS04b) from three independent tumor biopsies
which express and maintain episomal variant BPV-1 genomes.
All three of the cell lines contain variant BPV-1 genomes. We
therefore confirm yet again that sarcoids, and their derivative
cell lines, are associated with variant BPV-1 genomes (also see
below). To our knowledge, these are the first established cell
lines harboring variant BPV-1 derived from sarcoids, in addition
to our previously described sarc-1 cell line (Nixon et al., 2005).
A previous report described a sarcoid cell line MC-1. However,
the virus associated with MC-1 cells and their derivatives was a
non-oncogenic replication defective virus presumed to be an
endogenous equine retrovirus and a causative relationship be-
tween this virus and equine sarcoidswas not established (Cheevers
et al., 1982).
In addition, we have developed equine cell lines transformed
by the most common variant BPV-1 genome found in sarcoids.
All these cell lines, whether explanted from sarcoids or trans-
formed in vitro, show enhanced proliferation and increased life
span. The cell lines show the typical morphology of transformed
fibroblasts and five out of six lines are also capable of growth
in an anchorage independent fashion. Only the equine sarcoid
cells however can efficiently grow in low serum, suggesting that
additional events are needed for the onset of serum indepen-
dence in the S6 cells.
We have been repeatedly unable to generate equine cell lines
transformed by BPV-1 isolated from bovine warts, with which
we have successfully transformed both primary bovine
fibroblasts (from conjunctiva or palate) and established mouse
cells (NIH 3T3 and C127) (Jarrett et al., 1990; Campo and
Spandidos, 1983; unpublished). This point deserves particular
attention. We have previously shown that the BPV-1 genome
found in sarcoids is seldom identical to “bovine” wild-type
BPV-1, most frequently showing numerous nucleotide varia-
tions in genes, both synonymous and non-synonymous, and in
the LCR promoter/enhancer region (Chambers et al., 2003b;
Yuan et al., 2007a; Nasir and Reid, 2006; Nasir et al., 2007). We
have also shown that the variations in the LCR and in the E2
gene lead to increased function of these viral elements in equineqPalF (S6-2) and sarcoid derived fibroblasts (EqS01a) and control EqPalF cells.
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report that this enhanced function of viral variants is not
confined to individual genes/elements but encompasses the
whole genome, leading to the establishment of transformed cell
clones, the better studied of which (S6-1 to 3) show similar
characteristics to those of cell lines explanted from sarcoids.
Furthermore, in this study, cells transfected with BPV-1-S11
were unable to survive. S11 comprises the rare LCR variant V
and the rare E5 variant IV (Nasir et al., 2007). Only cells
transfected with S5 and S6 BPV-1 genomes were able to
survive. Both these BPV-1 genomes contain the most common
LCR variant II and the most common E5 variant Swiss I (Nasir
et al., 2007). These results strongly support our previous con-
clusions that variants of BPV-1 circulate at a higher frequency in
equids than in bovids and show that the most common sarcoid
BPV-1 variants are better suited to transformation of equine
cells.
Maintenance and expression of viral genomes
In all cell lines the BPV-1 genome is episomal and in more
than one copy, with the exception of EqS02a which only has
one copy.
The viral early and late genes are transcribed in all cell lines.
Perhaps not surprisingly the levels of BPV-1 RNA are pro-
portional to the levels of viral genomes. This is in full agreement
with the results of Bogaert et al. (2007) in sarcoid tumors in vivo.
The early proteins E1 and E2 are absolutely necessary for
replication andmaintenance of episomal viral DNA (Piirsoo et al.,
1996), and accordingly E1 and E2 RNAs are present in all cell
lines.
E5, E6 and E7 are the oncoproteins of BPV-1, with E5 and E6
having major roles and E7 enhancing their actions (Howley and
Lowy, 2007). The role of the papillomavirus E5 protein has been
reviewed recently (Suprynowicz et al., 2005). Briefly E5
transforms cells primarily through its interaction with, and acti-
vation of, the PDGF receptor, and interaction with, and disabling
of, the 16k subunit c of the vacuolar ATPase. In our equine cell
lines, the expression of E5 correlates positively with cellular
growth: the higher the levels of E5 RNA, the shorter the cells
doubling time (Figs. 4b, 5a). Furthermore, like in bovine cells
(Ashrafi et al., 2002;Marchetti et al., 2002;Marchetti et al., 2006;
Araibi et al., 2004, 2006; Tsirimonaki et al., 2006) E5 up-regulates
kinases and down-regulates MHC class I also in equine cells and
in sarcoids (in preparation), confirming its pivotal role in
establishment of infection and cell transformation.
The expression of BPV-1 E6 and E7 genes is similar. It is
known that BPV-1 E6 is a transcriptional regulator (Lamberti
et al., 1990) and additionally binds to both a calcium binding
protein (Chen et al., 1995) and to paxillin (Tong and Howley,
1997). This last interaction leads to disruption of the actin
cytoskeleton contributing to the transformed phenotype. The E5
proteins of BPV-1 and BPV-4 also lead to disruption of the
actin cytoskeleton in BovPalF cells (Tsirimonaki et al., 2006).
However, this study shows that expression of BPV-1 in EqPalFs
does not appear to have any discernible effect on the actin
cytoskeleton.BPV-1 E7, like all E7 proteins from ungulate fibropapillo-
maviruses, does not have a p105Rb binding site (Narechania
et al., 2004) and its precise role in aiding transformation has been
elusive. A recent report has shown that BPV-1 E7 prevents
apoptosis due to detachment from substrate (anoikis) and en-
hances the ability of the transformed cells to grow in an anchor-
age independent fashion (DeMasi et al., 2007). In our equine cell
lines, the ability to grow independently of substrate is roughly
proportional to the levels of E5, E6 and E7 RNAs. EqS04b
cells with the highest amount of E5, E6 and E7 RNA grow in
agar with a similar efficiency to the control bovine ConBPV-1
cells.
As bovine PalF cells transformed by BPV-1 E5 are capable
of anchorage independence (Tsirimonaki et al., 2006), at the
moment it is not possible to say which of the BPV-1 onco-
proteins is responsible for this cell transformation trait and to
what extent.
The late gene L1 is expressed in the cell lines. Expression of
L1, the major structural capsid protein, has been observed in
sarcoids although mature virions have not yet been found
(Barthold and Olson, 1978, Sundberg et al., 1984). The late
(structural) RNAs of papillomavirus are subjected to post-
transcriptional control and require the differentiation of
keratinocytes for their stability and translation into proteins
(Graham, in press). The situation in sarcoids, EqS and S6 cells
therefore resembles the situation in the fibroblastic portion of
BPV-1 induced fibropapillomas, where late RNAs can be
transcribed but not translated.
The tumor suppressor p53 is disabled in transformed equine
cells
One obstacle to cell transformation is the array of tumor
suppressor proteins which the cell employs to resist transfor-
mation. It is well known that papillomavirus disables
numerous tumor suppressors, particularly p105Rb and p53
(reviewed in Boulet et al., 2007). It has been shown that E6
from high-risk human papillomaviruses degrades p53 (Scheff-
ner et al., 1990) but BPV-1 E6 has been reported not to be able
to bind human p53 in vitro (Werness et al., 1990) or degrade
p53 in mouse C127 cells (Schiller et al., 1984) although it does
so in human mammary cells (Band et al., 1993). Surprisingly
the interaction between BPV-1 E6 and p53 has not been
investigated in the virus natural host cells, either bovine or
equine.
In the equine cell lines examined here, whether explanted
from sarcoids or transformed in vitro, p53 is not degraded but
stabilized, is almost totally cytoplasmic as previously reported
by us and by others (Johnston et al., 1996; Martens et al.,
2000; Nixon et al., 2005, Bogaert et al., 2007), and not
functional, as already described (Nixon et al., 2005). It is to be
noted that p53 function in sarcoid cells is not lost through
mutations as the p53 gene is wild-type in the tumor (Bucher
et al., 1996; Nasir et al., 1999), but probably because of the
almost total mis-location of the protein. It remains to be seen if
the cytoplasmic localization of p53 in sarcoid cells is due to
BPV-1 E6. Also the status of other tumor suppressor genes
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inducing genes are down-regulated in cell lines and in sarcoids
(in preparation).
Great advancements have been made in the understanding of
equine sarcoids but much still needs to be elucidated. The
availability of our panel of transformed equine cells presents the
best opportunity for a thorough analysis of sarcoid pathogenesis.
Methods and materials
Pathologic samples
Samples of equine fetal palate tissue were collected from an
aborted fetus at surgery. Sarcoid tumors were collected at
surgery/post mortem. All tissues were taken with informed
owner consent. The diagnosis of equine sarcoid was confirmed
by histopathological analysis following hematoxylin and eosin
staining.
Generation and establishment of equine palate fibroblasts
(EqPalFs) and equine sarcoid (EqS) fibroblasts
Tissue samples from fetal palate and sarcoids were finely
dissected and washed with Hanks Buffered Salt Solution
(HBSS) (Invitrogen Ltd, Paisley, UK) and incubated overnight
at 4 °C in 0.25% trypsin/HBSS. After removal of the trypsin
solution, samples were incubated at 37 °C for 30 min followed
by the addition of warm Dulbeccos Modified Eagles medium
(DMEM) supplemented with 10% FCS, 100 U/ml penicillin/
streptomycin, 1.25 μg/ml fungizone, Ampotericin B and
Ciproxin (Sigma, UK), 1% non-essential amino acids and 1%
essential amino acids (complete DMEM). The cell suspensions
were passed through a 100 μm nylon cell strainer (BD
Falcon™) and centrifuged. Resuspended cells were then seeded
into T25 flask at 1×106 cells per flask in 10 ml of complete
DMEM and incubated in a 37 °C humidified atmosphere of 5%
CO2 in air until cells reached confluence. Cells were passaged
by trypsinization and this stage was regarded as the first
passage. Equine Sarcoid tumor-derived fibroblasts were termed
EqS cells and the fetal palate fibroblasts termed EqPalFs. All
cells were maintained in culture in complete DMEM in a 37 °C
humidified atmosphere of 5% CO2 in air. Cells were routinely
tested for mycoplasma and were consistently negative.
Generation and establishment of EqPalF-BPV-1 transfected
cells
Rolling Circle Amplification (RCA) was performed as
described previously (Yuan et al., 2007b) to amplify the whole
BPV-1 genome from three sarcoid DNA samples, S5, S6 and
S11 from a previous study (Table 1). Products of RCA were
HindIII digested and separated by 0.8% agarose gel electro-
phoresis. For each sample an 8 kb band corresponding to the
BPV-1 genome was gel purified and cloned into a HindIII
digested pcDNA3.1(−) plasmid (Invitrogen Ltd) to produce
BPV-1 plasmids, pBPV-1-S5, pBPV-1-S6 and pBPV-1-S11.
T7 primer (Invitrogen Ltd) and a BPV-1/2 E5 specific primerBPVE5F were used to sequence the plasmids to confirm the
presence of BPV-1. The plasmids were then amplified in
E. coli and the BPV-1 genomes were HindIII digested from the
cloning vector followed by gel isolation and purification. The
genomes were re-circularized using T4 DNA ligase (Invitro-
gen Ltd). Circularized BPV-1 DNA was co-transfected with
pcDNA3.1 into EqPalF cells in a 6-well tissue culture plate
using Lipofectamine transfection reagent (Invitrogen Ltd)
following the supplier's recommended protocol. Similarly,
BPV-1 genome from a cattle papilloma was digested from
pBPV-1 (Campo and Coggins, 1982) and used in EqPalF co-
transfections as described above. Control transfections of
EqPalFs were carried out using empty plasmid pcDNA3.1(−)
and a GFP expressing plasmid pEGFPC3 (Invitrogen Ltd).
Transfections were repeated twice in triplicate. Transfected
cells were selected for 1 week in the presence of 75 μg/ml G418
(Invitrogen Ltd) followed by a further 2 weeks selection in
150 μg/ml G418. Selected G418 resistant cell colonies
were picked individually using sterile 6 mm stainless steel
cloning rings and expanded in 6-well plates. Once confluent,
cells were passaged by trypsinization and maintained as
monoclonal cell lines in selection (200 μg/ml G418). This
step was regarded as the first passage. Three transfected
colonies were individually picked and expanded. The three cell
clones were named EqPalFS6-1, EqPalFS6-2 and EqPalFS6-3
(these cell lines will be referred to as S6-1, S6-2 and S6-3,
respectively).
Southern blot hybridization
Southern blot analysis was performed using standard
protocols (Sambrook et al., 1989). Briefly, approximately 10
μg total cell DNA samples was digested with a single cutter,
HindIII, and subjected to 0.8% agarose gel electrophoresis.
The DNA was then transferred to nitrocellulose Hybond N+
membranes (GE Healthcare, UK). Membranes were hybridized
with a BPV-1 probe for 18 h at 60 °C, washed, air-dried and
exposed at −80 °C to x-ray films. The probe was labeled using
Prime-It II Random Primer Labeling Kit (Stratagene, La Jolla,
USA) with the Exo(−) Klenow enzyme and [α-32P] dCTP
(GE Healthcare, UK).
RT-PCR
Total RNAwas extracted from cells using the RNeasy Mini
Kit (Qiagen, Crawley, UK). Following DNase I treatment,
cDNA was synthesized using SuperScript First-Strand Synth-
esis System (Invitrogen). PCR reactions were performed using
Platinum Taq DNA polymerase (Invitrogen) on 2 μl cDNA
samples in a total volume of 20 μl with specific primers for
BPV-1 early gene E1, E2, E5, E6 or E7, or the late gene L1
(Supplementary data). Samples were initially denatured at
94 °C for 4 min followed by 35 cycles at 94 °C for 30 s, 55 °C
for 30 s and 72 °C for 30 s, with a final extension at 72 °C for
7 min. To ensure the absence of genomic DNA, RT-PCRs were
also performed on RNA samples in the absence of reverse
transcriptase.
359Z.Q. Yuan et al. / Virology 373 (2008) 352–361Real-time Absolute Quantitative PCR for viral load assessment
BPV-1/2 viral load was determined by real-time Absolute
Quantitative PCR (AQ-PCR) using a BPV-1/2 E7 primer probe
set as described previously (Yuan et al., 2007a). Briefly, AQ-
PCR was performed on 0.1 μg DNA samples on a 7500 Real
Time PCR System (Applied Biosystems, Warrington, UK) with
an amplification profile of 2 min at 50 °C, 2 min at 95 °C and 45
cycles of 15 s at 95 °C and 45 s at 60 °C. A serial dilution of the
pBPV-1-S6 plasmid was used to generate a standard curve and
equine GAPDH primer and probe set (Supplementary data) was
used as an internal control for normalization of input DNA
amount. Reactions were performed in triplicate. 0.1 μg of input
equine DNA was regarded as 32,680 genome equivalents of
equine cells based on the fact that a diploid equine cell contains
3×109 bp of total DNA of the mass of 3.06 pg. Accordingly,
BPV-1/2 viral load in equine cells is presented as number of
BPV-1/2 copies per genome equivalent (g.e.) of cell.
Real-time relative quantitative PCR for BPV-1 E5, E6 and E7
expression
Real-time Relative Quantitative PCR (RQ-PCR) was per-
formed on 2 μl cDNA samples (0.1 μg) using E5, E6 and E7
specific primer probe sets (Supplementary data). PCR reaction
mixes contained 0.2 μM forward and reverse primers, 0.1 μM
probe, 25 μl of 2× Platinum Quantitative PCR SuperMix-UDG
(Invitrogen, UK), 1 μl ROX Reference Dye and water to a final
volume of 50 μl. Reactions were performed on a 7500 Real Time
PCR System (Applied Biosystems) with an amplification profile
of 2 min at 50 °C, 2 min at 95 °C and 45 cycles of 15 s at 95 °C
and 45 s at 60 °C. GAPDH primer probe set (Supplementary
data) was used as an endogenous control and all reactions were
performed in triplicate. RQ-PCR using serial dilutions of
template verified that the efficiencies of amplification of BPV-
1 E5, E6, E7 and GAPDH, the internal reference, were ap-
proximately equal. The 2−ΔΔCt method (Livak and Schmittgen,
2001) was used to compare the relative expression levels of
BPV-1 E5, E6 and E7 genes among cell lines.
Cell proliferation assays
Assessment of cell proliferation and viability was deter-
mined using the Cell Proliferation Kit I (Roche). Briefly, 4×104
cells were seeded in 24-well tissue culture plates in DMEM
containing 10% FCS. MMT assays were performed in triplicate
every 24 h for a total of 7 days. Spectrophotometric absorbance
at 570 nm and 660 nm was measured, and the difference
between A570 and A660 was plotted as a function of time.
To determine cell population doubling times during the
exponential growth phase, 4×104 cells were seeded in 24-
well plates in 2 ml completed DMEM supplemented with 10%
FCS and cell number was counted every 24 h in triplicate wells.
The mean values were plotted on a log scale against time on a
linear scale. Population doubling (P.D.) was calculated using the
formula P.D.=3.32(log10 number of cells harvested−number of
cells seeded) (Scott et al., 2004).Anchorage independence and low serum growth assays
To assess anchorage independence growth, 2.0×105 cells
were added to 15 ml Methocel medium (1.0% methylcellulose,
30% FCS in complete F10 Ham's medium) and transferred to a
bacterial grade 100 mm Petri dish and allowed to grow for 2
weeks. Triplicates of each cell line were examined. Fetal bovine
conjunctiva cells transformed with BPV-1 (ConBPV-1) were
used as a positive control (Jarrett et al., 1990). The average
efficiency of colony formation was calculated as number of
colonies/number of cells. To assess growth in low serum, cells
were cultivated in 24-well plates as described above using
complete DMEM but supplemented with either serum free or
1.0% FCS. MTT assays were carried out as described above to
evaluate viability and proliferation of cells.
p53 and Ki67 immunocytochemistry
Cells were grown on coverslips in 6-well plates and expres-
sion of ki67 and p53 investigated using a two-step immuno-
histochemical technique using Dako EnVision kit (K4007 for
p53 and K4011 for Ki-67) following the manufacturer's instruc-
tions. Briefly, cells were fixed in acetone, rinsed with wash
buffer and the endogenous biotin activity quenched by a 5-
minute application of H2O2 solution. Coverslips were incubated
for 1 h at room temperature in the presence of primary antibody
(CM-1 p53 antibody (Novocastra Laboratories, UK) diluted
1:500 in 10 mM Tris Buffer Saline (TBS) and Ki-67 antibody
(Dako, Ely, UK) diluted 1:200 in 10 mM TBS. Coverslips were
then rinsed in 0.5% Tween20 in 10 mM TBS and incubated with
the appropriate labeled polymer-HRP anti-mouse or anti-rabbit
solution supplied with the Dako EnVision kit (Dako, UK) for
30 min. Cells were then stained with 3,3-diaminobenzidine and
counterstained with hematoxylin. The coverslips were washed
and mounted on a glass slide. For negative controls, sections
were incubated with a non-related serum instead of the primary
antibody.
Cytoimmunofluorescence
Cells were grown on glass coverslips for at least 2 days in
DMEM-10% FCS, and F-actin was labeled with tetramethylr-
hodamine-5-isothiocyanate TRITC-conjugated phalloidin.
Images were viewed, processed and photographed using a
Leica DMIRE2 confocal microscope and Leica Confocal
Software Lite Version (Germany).
Acknowledgments
We are grateful to Prof Iain Morgan for his critical reading of
the manuscript. This work was supported by The Horse Trust,
UK. MSC is a fellow of Cancer Research UK.
Appendix A. Supplementary data
Supplementary data associated with this article can be found,
in the online version, at doi:10.1016/j.virol.2007.11.037.
360 Z.Q. Yuan et al. / Virology 373 (2008) 352–361References
Amtmann, E., Muller, H., Sauer, G., 1980. Equine connective tissue tumors
contain unintegrated bovine papillomavirus DNA. J. Virol. 35, 962–964.
Araibi, E., Marchetti, B., Ashrafi, G.H., Campo, M.S., 2004. Down-regulation
of MHC class I in bovine papillomas. J. Gen. Virol. 85, 2809–2814.
Araibi, E.H., Marchetti, B., Dornan, E.S., Ashrafi, G.H., Dobromylskyj, M.,
Ellis, S.A., Campo, M.S., 2006. The E5 oncoprotein of BPV-4 does not
interfere with the biosynthetic pathway of non-classical MHC class I.
Virology 353, 174–183.
Ashrafi, G.H., Tsirimonaki, E., Marchetti, B., O'Brien, P.M., Sibbet, G.J.,
Andrew, L., Campo, M.S., 2002. Down regulation of MHC class I by bovine
papillomavirus E5 oncoproteins. Oncogene 21, 248–259.
Band, V., Dalal, S., Delmolino, L., Rophy, E., 1993. Enhanced degradation of
p53 protein in HPV-6 and BPV-1 E6 in immortalised human mammary
epithelial cell. EMBO J. 12, 1847–1852.
Barthold, S.W., Olson, C., 1978. Common membrane neo-antigens on bovine
papilloma virus-induced fibroma cells from cattle and horses. Am. J. Vet.
Res. 39, 1643–1645.
Bloch, N., Breen, M., Spradbrow, P.B., 1994. Genomic sequences of bovine
papillomaviruses in formalin-fixed sarcoids from Australian horses revealed
by polymerase chain reaction. Vet. Microbiol. 41, 163–172.
Bogaert, L., Van Poucke, M., De Baere, C., Dewulf, J., Peelman, L., Ducatelle,
R., Gasthuys, F., Martens, A., 2007. Bovine papillomavirus load and mRNA
expression, cell proliferation and p53 expression in four clinical types of
equine sarcoid. J. Gen. Virol. 88, 2155–2161.
Boulet, G., Horvath, C., Broeck, D.V., Sahebali, S., Bogers, J., 2007. Human
papillomavirus: E6 and E7 oncogenes. Int. J. Biochem. Cell Biol. 39,
2006–2011.
Bucher, K., Szalai, G., Marti, E., Griot-Wenk, M.E., Lazary, S., Pauli, U., 1996.
Tumour suppressor gene p53 in the horse: identification, cloning, sequencing
and a possible role in the pathogenesis of equine sarcoid. Res. Vet. Sci. 61,
114–119.
Campo, M.S., Coggins, L.W., 1982. Molecular cloning of bovine papilloma-
virus genomes and comparison of their sequence homologies by hetero-
duplex mapping. J. Gen. Virol. 63, 255–264.
Campo, M.S., Spandidos, D.A., 1983. Molecularly cloned bovine papilloma-
virus DNA transforms mouse fibroblasts in vitro. J. Gen. Virol. 64 (Pt 3),
549–557 Mar.
Carr, E.A., Theon, A.P., Madewell, B.R., Hitchcock,M.E., Schlegel, R., Schiller,
J.T., 2001. Expression of a transforming gene (E5) of bovine papillomavirus
in sarcoids obtained from horses. Am. J. Vet. Res. 62, 1212–1217.
Chambers, G., Ellsmore, V.A., O'Brien, P.M., Reid, S.W.J., Love, S., Campo,
M.S., Nasir, L., 2003a. Sequence variants of bovine papillomavirus E5
detected in equine sarcoids. Virus Res. 96, 141–145.
Chambers,G., Ellsmore, V.A., O'Brien, P.M., Reid, S.W.J., Love, S., Campo,M.S.,
Nasir, L., 2003b.Association of bovine papillomavirus with the equine sarcoid.
J. Gen. Virol. 84, 1055–1062.
Cheevers, W.P., Roberson, S.M., Brassfield, A.L., Davis, W.C., Crawford, T.B.,
1982. Isolation of a retrovirus from cultured equine sarcoid tumor cells.
Am. J. Vet. Res. 43, 804–806.
Chen, J.J., Reid, C.E., Band, V., Androphy, E.J., 1995. Interaction of papillo-
mavirus E6oncoproteins with a putative calcium-binding protein. Science 269,
529–531.
DeMasi, J., Chao, M.C., Kumar, A.S., Howley, P.M., 2007. Bovine
papillomavirus E7 oncoprotein inhibits anoikis. J. Virol. 81, 9419–9425.
Gorman, N.T., 1985. Equine sarcoid-time for optimism. Equine Vet. J. 17,
412–414.
Graham, S.V., in press. Papillomavirus 3′ UTR regulatory elements. Front.
Biosci. in press.
Howley, P.M., Lowy,D.R., 2007. Papillomaviruses, In: Knipe, D.M.,Howley, P.M.
(Eds.), Fields Virology, 5th ed. Lippincott,Williams andWilkins, Philadelphia,
PA, pp. 2299–2354.
Jackson, C., 1936. The incidence and pathology of tumours of domestic animals
in South Africa. Onderstepoort J. Vet. Sci. Anim. Ind. 6, 378–385.
Jarrett, W.F.H., O’Neil, B.W., Laird, H.M., Smith, K.T., Campo, M.S., 1990.
Studies on vaccination against papillomaviruses: 1. A comparison of purifiedvirus, tumour extract and transformed cells in prophylactic vaccination.
Vet. Rec. 126, 473–475.
Johnston, H.M., Thompson, H., Pirie, H.M., 1996. p53 immunohistochemistry
in domestic animal tumours. Eur. J. Vet. Pathol. 2, 135–140.
Lamberti, C., Morrissey, L.C., Grossman, S.R., Androphy, E.J., 1990.
Transcriptional activation by the papillomavirus E6 zinc finger oncoprotein.
EMBO J. 9, 1907–1913.
Lancaster, W.D., Theilin, G.H., Olson, C., 1979. Hybridization of bovine
papilloma virus type 1 and type 2 DNA from virus-induced hamster tumours
and naturally occurring equine tumours. Equine Sarcoid. Intervirol. 11,
227–233.
Livak, K.J., Schmittgen, T.D., 2001. Analysis of relative gene expression data
using real-time quantitative PCR and the 2(−Delta Delta C(T)). Methods 25,
402–408.
Marchetti, B., Ashrafi, G.H., Tsirimonaki, E., O'Brien, P.M., Campo, M.S.,
2002. The papillomavirus oncoprotein E5 retains the major histocompat-
ibility class I in the Golgi apparatus and prevents its transport to the cell
surface. Oncogene 21, 7808–7816.
Marchetti, B., Ashrafi, G.H., Dornan, E., Araibi, E.H., Ellis, S.A., Campo, M.S.,
2006. The E5 protein of BPV-4 interacts with the heavy chain of MHC class
I and irreversibly retains the MHC complex in the Golgi apparatus.
Oncogene 27, 2254–2263.
Martens, A., De Moor, A., Demeulemeester, J., Ducatelle, R., 2000. Histopatho-
logical characteristics of five clinical types of equine sarcoid. Res. Vet. Sci. 69,
295–300.
Martens, A., DeMoor, A., Ducatelle, R., 2001. PCR detection of bovine papilloma
virusDNA in superficial swabs and scrapings fromequine sarcoids.Vet. J. 161,
280–286.
Narechania, A., Terai, M., Chen, Z., DeSalle, R., Burk, R.D., 2004. Lack of the
canonical pRB-binding domain in the E7ORFof artiodactyl papillomaviruses
is associated with the development of fibropapillomas. J. Gen. Virol. 85,
1243–1250.
Nasir, L., Reid, S.W., 1999. Bovine papillomaviral gene expression in equine
sarcoid tumours. Virus Res. 61, 171–175.
Nasir, L., Reid, S.W.J., 2006. ‘BPV in Equine Sarcoids’ in Papillomavirus
Research: FromNatural History to Vaccines and Beyond.MS Campo Caister
Academic Press (ISBN: 1-904455-04-2).
Nasir, L., Mcfarlane, S.T., Reid, S.W.J., 1999. Mutational status of the tumour
suppressor gene (p53) in donkey sarcoid tumours. Vet. J. 157, 99–101.
Nasir, L., Gault, E., Morgan, I.M., Chambers, G., Ellsmore, V., Campo, M.S.,
2007. Identification and functional analysis of sequence variants in the long
control region and the E2 open reading frame of bovine papillomavirus type
1 isolated from equine sarcoids. Virology 364, 355–361.
Nixon, C., Chambers, G., Ellsmore, V., Campo,M.S., Burr, P., Argyle, D.J., Reid,
S.W., Nasir, L., 2005. Expression of cell cycle associated proteins cyclin A,
CDK-2, p27kip1 and p53 in equine sarcoids. Cancer Lett. 221, 237–245.
Otten, N., von Tscharner, C., Lazary, S., Antczak, D.F., Gerber, H., 1993. DNA
of bovine papillomavirus type 1 and 2 in equine sarcoids: PCR detection and
direct sequencing. Arch. Virol. 132, 121–131.
Pascoe, R.R., Summers, P.M., 1981. Clinical survey of tumours and tumour-like
lesions in horses in south east Queensland. Equine Vet. J. 13, 235–239.
Piirsoo, M., Ustav, E., Mandel, T., Stenlund, A., Ustav, M., 1996. Cis and trans
requirements for stable episomal maintenance of the BPV-1 replicator.
EMBO J. 15, 1–11.
Ragland, W.H., Keown, G.H., Spencer, G.R., 1970. Equine sarcoid. Equine Vet.
J. 2, 2–11.
Reid, S.W., Smith, K.T., Jarrett, W.F., 1994. Detection, cloning and characterisa-
tion of papillomaviral DNA present in sarcoid tumours of Equus asinus.
Vet. Rec. 135, 430–432.
Sambrook, J., Fritsch, E.F., Maniatis, T., 1989.Molecular Cloning: A Laboratory
Manual, Second edition. Cold Spring Harbor Laboratory Press, Cold Spring
Harbor, New York, USA.
Scheffner, M., Werness, B., Huibregtse, J., Levine, A., Howley, P., 1990. The E6
oncoprotein encoded by human papillomavirus type 16 and 18 promotes the
degradation of p53. Cell 63, 1129–1136.
Schiller, J.T., Vass, W.C., Lowy, D.R., 1984. Identification of a second
transforming region in bovine papillomavirus DNA. Proc. Natl. Acad. Sci.
U. S. A. 81, 7880–7884.
361Z.Q. Yuan et al. / Virology 373 (2008) 352–361Scott, L.A., Vass, J.K., Parkinson, E.K., Gillespie, D.A., Winnie, J.N., Ozanne,
B.W., 2004. Invasion of normal human fibroblasts induced by v-Fos is
independent of proliferation, immortalization, and the tumor suppressors
p16INK4a and p53. Mol. Cell. Biol. 24, 1540–1559.
Sundberg, J.P., Junge, R.E., Lancaster, W.D., 1984. Immunoperoxidase
localization of papillomaviruses in hyperplastic and neoplastic epithelial
lesions of animals. Am. J. Vet. Res. 45, 1441–1446.
Suprynowicz, F.A., Disbrow, G.L., Simic, V., Schlegel, R., 2005. Are trans-
forming properties of the bovine papillomavirus E5 protein shared by E5
from high-risk human papillomavirus type 16? Virology 332, 102–113.
Tong, X., Howley, P.M., 1997. The bovine papillomavirus E6 oncoprotein
interacts with paxillin and disrupts the actin cytoskeleton. Proc. Natl. Acad.
Sci. U. S. A. 29, 4412–4417.Tsirimonaki, E., Ullah, R.,Marchetti, B., Ashrafi, G.H.,McGarry, L., Ozanne, B.,
Campo, M.S., 2006. Similarities and differences between the E5 oncopro-
teins of bovine papillomaviruses type 1 and type 4: cytoskeleton, motility and
invasiveness in E5-transformed bovine and mouse cells. Virus Res. 115,
158–168.
Werness, B.A., Levine, A.J., Howley, P.M., 1990. Association of human
papillomavirus types 16 and 18 E6 proteins with p53. Science 248, 76–79.
Yuan, Z., Gallagher, A., Gault, E.A., Campo, M.S., Nasir, L., 2007a. Bovine
papillomavirus infection in equine sarcoids and in bovine bladder cancers.
Vet. J. 174, 599–604.
Yuan, Z., Philbey, A.W., Gault, E.A., Campo, M.S., Nasir, L., 2007b. Detection
of bovine papillomavirus type 1 genomes and viral gene expression in
equine inflammatory skin conditions. Virus Res. 124, 245–249.
